Company Pliant Therapeutics, Inc.

PLRX

US7291391057

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Pliant Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
11.88 ^USD	-0.17%		-2.54%	-34.40%

Mar. 12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
Mar. 05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of Î±vÃ6 and Î±vÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of Î±vÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of Î±vÃ8 and Î±vÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Number of employees: 158

USD in Million	2022	Weight	2023	Weight	Delta
Novel Therapies 100.0 %	10	100.0 %	2	100.0 %	-83.69%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	10	100.0 %	2	100.0 %	-83.69%

Managers	Title	Age	Since
Bernard Coulie CEO	Chief Executive Officer	58	16-01-31
Bill DeGrado		-	-
Keith Cummings DFI	Director of Finance/CFO	47	18-11-30
Gregory P. Cosgrove CTO	Chief Tech/Sci/R&D Officer	-	21-01-03
Eric Lefebvre CTO	Chief Tech/Sci/R&D Officer	60	18-04-30
Scott Turner CTO	Chief Tech/Sci/R&D Officer	53	21-06-30
Christopher Keenan IRC	Investor Relations Contact	-	20-10-31
Minnie Kuo PRN	Corporate Officer/Principal	-	23-09-13
Katerina Leftheris PRN	Corporate Officer/Principal	-	-
Rik Derynck PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
David Pyott BRD	Director/Board Member	70	21-01-11
Suzanne Bruhn BRD	Director/Board Member	60	16-06-30
Gayle Crowell BRD	Director/Board Member	73	20-01-07
Ho Young Huh CHM	Chairman	54	17-11-30
Bernard Coulie CEO	Chief Executive Officer	58	16-01-31
Thomas McCourt BRD	Director/Board Member	66	23-03-05
Darren Cline BRD	Director/Board Member	59	23-03-05
John Curnutte BRD	Director/Board Member	72	17-07-31
Smital Shah BRD	Director/Board Member	48	19-03-13
Katharine Knobil BRD	Director/Board Member	60	22-09-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,239,176	56,195,983 ( 93.29 %)	0	93.29 %

Name	Equities	%	Valuation
Deep Track Capital LP 9.545 %	5,750,000	9.545 %	86 M $
BlackRock Advisors LLC 7.502 %	4,519,278	7.502 %	67 M $
Fidelity Management & Research Co. LLC 6.579 %	3,963,418	6.579 %	59 M $
T. Rowe Price International Ltd. 6.285 %	3,785,916	6.285 %	56 M $
First Light Asset Management LLC 5.963 %	3,591,776	5.963 %	54 M $
Laurion Capital Management LP 5.949 %	3,583,567	5.949 %	53 M $
Vanguard Fiduciary Trust Co. 5.089 %	3,065,869	5.089 %	46 M $
CHI Advisors LLC 5.004 %	3,014,199	5.004 %	45 M $
Blue Owl Healthcare Opportunities Advisors LLC 4.987 %	3,004,199	4.987 %	45 M $
Redmile Group LLC 4.477 %	2,696,648	4.477 %	40 M $

Pliant Therapeutics, Inc.

260 Littlefield Avenue

94080, South San Francisco

+650 481 6770

http://www.pliantrx.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.88 USD

Average target price

43 USD

Spread / Average Target

+261.95%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
PLIANT THERAPEUTICS, INC.	-34.40%	718M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals